News
-
-
PRESS RELEASE
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
Newron Pharmaceuticals S.p.A. announces agreement with EIB to extend 2018 Finance Contract tranche repayment dates to June 28, 2028, focusing on lead drug candidate evenamide for treatment-resistant schizophrenia -
-
-
-
-
-
PRESS RELEASE
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach -
-
PRESS RELEASE
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai
